2023
DOI: 10.1371/journal.pdig.0000178
|View full text |Cite
|
Sign up to set email alerts
|

Wearable sensor-based performance status assessment in cancer: A pilot multicenter study from the Alliance for Clinical Trials in Oncology (A19_Pilot2)

Abstract: Clinical performance status is designed to be a measure of overall health, reflecting a patient’s physiological reserve and ability to tolerate various forms of therapy. Currently, it is measured by a combination of subjective clinician assessment and patient-reported exercise tolerance in the context of daily living activities. In this study, we assess the feasibility of combining objective data sources and patient-generated health data (PGHD) to improve the accuracy of performance status assessment during ro… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 29 publications
0
2
0
Order By: Relevance
“…The model proposed here is entirely reliant on remote data collection, thus increasing accessibility to a broader and more diverse representation of patients while also promoting more equitable access to care. 69 , 70 Finally, we emphasize that all components of our multi‐domain model have already been deployed individually in the oncology field, 56 , 70 as well as by patients themselves using over‐the‐counter products. 39 Although validation, usability, and pilot testing is important when assessing and selecting suitable DHTs, moving our proposed model beyond feasibility studies will require multi‐institutional efforts that are most successful via precompetitive collaborations.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The model proposed here is entirely reliant on remote data collection, thus increasing accessibility to a broader and more diverse representation of patients while also promoting more equitable access to care. 69 , 70 Finally, we emphasize that all components of our multi‐domain model have already been deployed individually in the oncology field, 56 , 70 as well as by patients themselves using over‐the‐counter products. 39 Although validation, usability, and pilot testing is important when assessing and selecting suitable DHTs, moving our proposed model beyond feasibility studies will require multi‐institutional efforts that are most successful via precompetitive collaborations.…”
Section: Discussionmentioning
confidence: 99%
“…A more complex combination of measurements was tested by Wood et al. (2023) who captured in‐laboratory 6MWT and cardiopulmonary exercise testing (CPET) followed by 6 weeks of remote data collection using a wrist‐worn DHT (containing an accelerometer, altimeter, and optical light sensor) with intermittent ePROs 56 . Usable 6MWT and CPET data were obtained in 68% of patients undergoing chemotherapy or hematopoietic stem cell transplant; in contrast, 84% had usable data from the wrist‐worn DHT and 73% had usable data from both the wrist‐worn DHT and ePROs.…”
Section: Functional Status Is a Multi‐domain Aspect Of Healthmentioning
confidence: 99%
“…Many reports and research results have highlighted the importance of new technologies such as wearables in oncology [40][41][42][43], but most of these are focused on physical activity trackers in cancer populations with good performance [44] or in the survivorship setting [45](ref). Only a few scientific reports deal with the challenges met when applying wearables in the oncological setting.…”
Section: Introductionmentioning
confidence: 99%